What does PARC ELISABETH PHARMA do?

PARC ELISABETH PHARMA is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Private Limited, started on 27 January 2015, 1 establishment.

What is the address of PARC ELISABETH PHARMA?

The registered office of PARC ELISABETH PHARMA is located at Frans Gasthuislaan 2, 1083 Ganshoren.

Is PARC ELISABETH PHARMA still active?

Yes. According to the CBE (16 September 2026) PARC ELISABETH PHARMA is active, legal situation “Normale toestand”, started on 27 January 2015.

Is PARC ELISABETH PHARMA registered on Peppol?

Yes, PARC ELISABETH PHARMA is registered on the Peppol network with ID 0208:0578934701.

What is the enterprise number of PARC ELISABETH PHARMA?

The enterprise number of PARC ELISABETH PHARMA is BE0578934701.

When was PARC ELISABETH PHARMA founded?

PARC ELISABETH PHARMA was founded on 27 January 2015.

Who are the directors of PARC ELISABETH PHARMA?

According to the 2025 annual accounts, the directors of PARC ELISABETH PHARMA are: Gulnar Sadikova.

Is PARC ELISABETH PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 January 2015; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PARC ELISABETH PHARMA make in 2025?

PARC ELISABETH PHARMA recorded a loss after taxes of € 12,285 in financial year 2025.

What is the revenue of PARC ELISABETH PHARMA?

In its most recent annual accounts (2025), PARC ELISABETH PHARMA reported revenue of € 491,912.

PARC ELISABETH PHARMA (Private Limited) - Ganshoren

Dossier PARC ELISABETH PHARMA, printed on 16 September 2026 from databakkes.be/en/0578934701/parc-elisabeth-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 5 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PARC ELISABETH PHARMA from Ganshoren, company number BE0578934701, closed financial year 2025 with a result of € -12,285 after tax. For that financial year PARC ELISABETH PHARMA recorded revenue of € 491,912 and equity of € -63,400. Compared with financial year 2024, the result moved from € -3,024 to € -12,285. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on March 4, 2026.

What it is worth Caution

€ -63,400

▼ € 12,285 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -12,285

▼ 306 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 78

▼ 98% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -69,600.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost estimate Staff cost at a one-person company Staff Only people on the payroll count here.€ 422 Likely the director’s social contribution or pension premium.The director’s pay Already netted into the gross margin, not shown separately in the accounts. Typical for one-person companies € 45,000 gross per year minimum for the reduced tax rate≈ € 2,100 net per month after contributions, tax and usually some benefits in kind, roughly Assumption based on the chart of accounts, not a figure from the source.

€ 422

No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.

Vehicles and equipment

€ 3,100

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 215,037

▼ 14% vs 2024

€ 45,000 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 46,627

▼ 37% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 10,451

▼ 48% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	-	-	-	€ 491,912 Revenue 2025: € 491,912 First fiscal year in the series
Gross margin	€ 56,984 Gross margin 2022: € 56,984 First fiscal year in the series	€ 70,995 Gross margin 2023: € 70,995 ▲ 25% vs 2022 (€ 56,984) Favourable step	€ 69,418 Gross margin 2024: € 69,418 ▼ 2% vs 2023 (€ 70,995) Unfavourable step	€ 41,547 Gross margin 2025: € 41,547 ▼ 40% vs 2024 (€ 69,418) Unfavourable step	▼ 40%
Profit after taxes	€ -11,534 Profit after taxes 2022: € -11,534 First fiscal year in the series	€ -439 Profit after taxes 2023: € -439 ▲ € 11,095 vs 2022 (€ -11,534) Favourable step	€ -3,024 Profit after taxes 2024: € -3,024 ▼ € 2,585 vs 2023 (€ -439) Unfavourable step	€ -12,285 Profit after taxes 2025: € -12,285 ▼ € 9,261 vs 2024 (€ -3,024) Unfavourable step	▼ € 9,261
Equity	€ -47,652 Equity 2022: € -47,652 First fiscal year in the series	€ -48,091 Equity 2023: € -48,091 ▼ € 439 vs 2022 (€ -47,652) Unfavourable step	€ -51,115 Equity 2024: € -51,115 ▼ € 3,024 vs 2023 (€ -48,091) Unfavourable step	€ -63,400 Equity 2025: € -63,400 ▼ € 12,285 vs 2024 (€ -51,115) Unfavourable step	▼ € 12,285
Total debts	€ 499,018 Total debts 2022: € 499,018 First fiscal year in the series	€ 455,193 Total debts 2023: € 455,193 ▼ 9% vs 2022 (€ 499,018) Favourable step	€ 431,138 Total debts 2024: € 431,138 ▼ 5% vs 2023 (€ 455,193) Favourable step	€ 359,704 Total debts 2025: € 359,704 ▼ 17% vs 2024 (€ 431,138) Favourable step	▼ 17%
Cash	€ 5,653 Cash 2022: € 5,653 First fiscal year in the series	€ 6,949 Cash 2023: € 6,949 ▲ 23% vs 2022 (€ 5,653) Favourable step	€ 4,334 Cash 2024: € 4,334 ▼ 38% vs 2023 (€ 6,949) Unfavourable step	€ 78 Cash 2025: € 78 ▼ 98% vs 2024 (€ 4,334) Unfavourable step	▼ 98%
Retained profit	€ -53,852 Retained profit 2022: € -53,852 First fiscal year in the series	€ -54,291 Retained profit 2023: € -54,291 ▼ € 439 vs 2022 (€ -53,852) Unfavourable step	€ -57,315 Retained profit 2024: € -57,315 ▼ € 3,024 vs 2023 (€ -54,291) Unfavourable step	€ -69,600 Retained profit 2025: € -69,600 ▼ € 12,285 vs 2024 (€ -57,315) Unfavourable step	▼ € 12,285
Bank debt	€ 341,238 Bank debt 2022: € 341,238 First fiscal year in the series	€ 306,107 Bank debt 2023: € 306,107 ▼ 10% vs 2022 (€ 341,238) Favourable step	€ 250,656 Bank debt 2024: € 250,656 ▼ 18% vs 2023 (€ 306,107) Favourable step	€ 215,037 Bank debt 2025: € 215,037 ▼ 14% vs 2024 (€ 250,656) Favourable step	▼ 14%
Balance sheet total	€ 451,366 Balance sheet total 2022: € 451,366 First fiscal year in the series	€ 407,102 Balance sheet total 2023: € 407,102 ▼ 10% vs 2022 (€ 451,366) Unchanged	€ 380,023 Balance sheet total 2024: € 380,023 ▼ 7% vs 2023 (€ 407,102) Unchanged	€ 296,304 Balance sheet total 2025: € 296,304 ▼ 22% vs 2024 (€ 380,023) Unchanged	▼ 22%

Key figures of PARC ELISABETH PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PARC ELISABETH PHARMA?

What happened at PARC ELISABETH PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 4, 2026 New annual accounts for financial year 2025: loss of € 12,285. Source: NBB ↗
2023 Gulnar Sadikova became a director. NBB
Jan 27, 2015 New establishment in Ganshoren. KBO
Jan 27, 2015 Start of the company according to the CBE. KBO

In short

From € 11,534 loss in 2022 to € 12,285 loss in 2025.

Paid € 44,287 in corporate taxes since 2022.

Original PDFs at the National Bank ↗

A new publication or filing at PARC ELISABETH PHARMA? We notify you, reason included.

Follow PARC ELISABETH PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Gulnar Sadikova

PARC ELISABETH PHARMA

Behind PARC ELISABETH PHARMA is Gulnar Sadikova.

See the full network in the app

Directors

According to the 2025 annual accounts

Gulnar Sadikova

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Frans Gasthuislaan 2

1083 Ganshoren

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0578.934.701
VAT number: BE 0578.934.701
Registered office: Frans Gasthuislaan 2, 1083 Ganshoren
Names & denominations: PARC ELISABETH PHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 27 January 2015
Peppol: Active · Active since 4 Feb 2026
Activities · NACE: Vervaardiging van geneesmiddelen

View on CBE Public ↗ Annual accounts (NBB) ↗